• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BioSphere taps FDA for investigational exemption

BioSphere taps FDA for investigational exemption

October 27, 2009 By MassDevice staff

BioSphere Medical Inc. wants the Food & Drug Administration to OK a clinical trial of its QuadraSphere liver cancer treatment.

The Rockland, Mass.-based microsphere maker said it’s asked the federal watchdog agency for an investigational device exemption to study whether its microspheres can be combined with the chemotherapeutic agent doxorubicin to effectively treat liver cancer.

According to the proposed study’s protocols, the treatment, conventional transarterial chemoembolization, would take two stages. In the first, a concentrated dose of doxorubicin would be injected directly into the blood vessels feeding the tumor. The second stage would see the injection of the microsphere into the same vessel, to embolize or block the vessel. The second stage not only cuts off the blood supply to the tumor but, in theory, would leave the chemotherapeutic drug in longer and more targeted contact with the cancerous tissue.

BioSphere said the QuadraSphere product is essentially identical to its HepaSphere, which has already won CE Mark approval in the European Union for the doxorubicin embolization procedure. The proposed IDE trial, involving about 15 centers in the U.S., EU and Brazil would begin enrolling patients within 60 days of FDA approval; it would take about a year to complete enrollment. BioSphere said it plans to file for pre-market approval from the FDA 12 months after concluding the IDE study, should it win approval.

The company recently cited data from another trial showing that uterine artery embolization treatment outperforms laparoscopic occlusion of uterine arteries in treating fibroids.

Filed Under: Business/Financial News, Oncology Tagged With: Gift Bans

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy